Look no further than GlaxoSmithKline shedding its consumer ... and deliver far higher returns for shareholders, research finds. Building the new vision starts with defining a credible and meaningf ...

International drug giant GSK plc is moving its vaccine R&D and infectious disease teams to Cambridge from Maryland, and plans to expand its footprint here.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares opened today ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s shares opened today at p1,435.00. Leverage the ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines (Andy Buchanan/PA) Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales ...

If approved, the new presentation will offer a convenient administration option to healthcare professionals Globally, up to 1 in 3 adults will develop shingles in their lifetime 1,2,3,4 Over 25 ...

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover set to lift by between 3% and 5%. It added that it expects further growth to be boosted by its strong ...

The lawsuit claims GlaxoSmithKline replaced Flovent with ... or their parents could not afford to pay for it out of pocket since the new generic form was not covered.” ...

still linger, and GSK has to prove its drug development pipeline is packed with new blockbuster treatments.